Andres Ruiz Briseno - 01 Jul 2023 Form 3 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Role
Title: SVP, Head of Finance and Investor Relations Exhibit 24.1 - Power of Attorney
Signature
/s/ Jason Throne, as Attorney-in-Fact for Andres Ruiz Briseno
Issuer symbol
IDYA
Transactions as of
01 Jul 2023
Net transactions value
$0
Form type
3
Filing time
03 Jul 2023, 19:50:07 UTC
Next filing
06 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IDYA Common Stock 34,531 01 Jul 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IDYA Stock Option (Right to Buy) 01 Jul 2023 Common Stock 60,000 $22.30 Direct F1
holding IDYA Stock Option (Right to Buy) 01 Jul 2023 Common Stock 28,750 $12.86 Direct F2
holding IDYA Stock Option (Right to Buy) 01 Jul 2023 Common Stock 42,500 $17.04 Direct F3
holding IDYA Stock Option (Right to Buy) 01 Jul 2023 Common Stock 22,500 $23.23 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on the first anniversary measured from November 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F2 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F3 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F4 25% of the shares subject to the option vest on the first anniversary measured from July 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Title: SVP, Head of Finance and Investor Relations Exhibit 24.1 - Power of Attorney